Sorted By Test Name - Mayo Medical Laboratories

LID
8382
FLIMB
91635
LIME
82360
0.2-3 mcg/mL plasma.
Test Performed by: NMS Labs
3701 Welsh Road
P.O. Box 433A
Willow Grove, PA 19090-0437
Lidocaine, Serum
Clinical Information: Lidocaine is commonly used as a local anesthetic, but is also effective at
controlling ventricular arrhythmia and ventricular fibrillation in children and adults. For cardiac therapy,
optimal therapeutic response is seen when serum concentrations are between 1.5 mcg/mL and 5.0
mcg/mL. Lidocaine is 50% protein-bound, primarily to alpha-1-acid glycoprotein; concentrations of this
protein increase after myocardial infarction, which may decrease the amount of free lidocaine and thus its
efficacy. Lidocaine undergoes extensive first-pass hepatic metabolism and thus is not administered orally.
It is eliminated via renal clearance, with a half-life of approximately 1.5 hours. Diseases that reduce
hepatic or renal function reduce clearance and prolong elimination of lidocaine. Toxicity occurs when the
concentration of lidocaine is >6.0 mcg/mL and is usually associated with symptoms of central nervous
system excitation, light-headedness, confusion, dizziness, tinnitus, and blurred or double vision. This can
be accompanied by bradycardia and hypotension leading to cardiovascular collapse.
Useful For: Assessing optimal dosing during the acute management of ventricular arrhythmias
following myocardial infarction or during cardiac manipulation such as surgery Assessing potential
toxicity
Interpretation: Optimal response to lidocaine occurs when the serum concentration is between 1.5
mcg/mL to 5.0 mcg/mL. Toxicity is more likely when concentrations exceed 6.0 mcg/mL.
Reference Values:
Therapeutic concentration: 1.5-5.0 mcg/mL
Toxic concentration: >6.0 mcg/mL
Clinical References: 1. Valdes R Jr, Jortani SA, Gheorghiade M: Standards of laboratory practice:
cardiac drug monitoring. National Academy of Clinical Biochemistry. Clin Chem 1998; 44(5):1096-1109
2. "Lidocaine" In Physicianâ€s Desk Reference. November, 2009 3. Harrison DC: Should lidocaine be
administered routinely to all patients after acute myocardial infarction? Circulation 1978;58:581-584
Limb Girdle Muscular Dystrophy Evaluation
Reference Values:
A final report will be faxed under separate cover.
Test Performed By: Athena Diagnostics
377 Plantation St.
Four Biotech Park
Worcester, MA 01605
Lime, IgE
Clinical Information: Clinical manifestations of immediate hypersensitivity (allergic) diseases are
caused by the release of proinflammatory mediators (histamine, leukotrienes, and prostaglandins) from
immunoglobulin E (IgE)-sensitized effector cells (mast cells and basophils) when cell-bound IgE
antibodies interact with allergen. In vitro serum testing for IgE antibodies provides an indication of the
immune response to allergen(s) that may be associated with allergic disease. The allergens chosen for
testing often depend upon the age of the patient, history of allergen exposure, season of the year, and
clinical manifestations. In individuals predisposed to develop allergic disease(s), the sequence of
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 1108